Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.
3.

Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes.

Cawthorne MA, Carroll MJ, Levy AL, Lister CA, Sennitt MV, Smith SA, Young P.

Int J Obes. 1984;8 Suppl 1:93-102.

PMID:
6152558
5.
6.

Improved glycemic control in C57Bl/KsJ (db/db) mice after treatment with the thermogenic beta-adrenoceptor agonist, BRL 26830.

Carroll MJ, Lister CA, Sennitt MV, Stewart-Long N, Cawthorne MA.

Diabetes. 1985 Nov;34(11):1198-204.

PMID:
2864298
7.

Effect of a novel thermogenic beta-adrenoceptor agonist (BRL 26830) on insulin resistance in soleus muscle from obese Zucker rats.

Challiss RA, Budohoski L, Newsholme EA, Sennitt MV, Cawthorne MA.

Biochem Biophys Res Commun. 1985 Apr 30;128(2):928-35.

PMID:
2986630
8.
9.

Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.

Arch JR, Ainsworth AT, Ellis RD, Piercy V, Thody VE, Thurlby PL, Wilson C, Wilson S, Young P.

Int J Obes. 1984;8 Suppl 1:1-11.

PMID:
6152555
11.

Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice.

Yoshida T, Hiraoka N, Yoshioka K, Hasegawa G, Kondo M.

Endocrinol Jpn. 1991 Aug;38(4):397-403.

12.
13.

Effects of a beta 3-adrenoceptor agonist, BRL 26830A, on insulin and glucagon release in mice.

Yoshida T, Hiraoka N, Kondo M.

Endocrinol Jpn. 1991 Dec;38(6):641-6.

14.

Anti-hyperglycaemic action of BRL 26830, a novel beta-adrenoceptor agonist, in mice and rats.

Sennitt MV, Arch JR, Levy AL, Simson DL, Smith SA, Cawthorne MA.

Biochem Pharmacol. 1985 Apr 15;34(8):1279-85.

PMID:
2859857
15.

Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice.

Schaeffer P, Bernat A, Arnone M, Manara L, Gallas JF, Dol-Gleizes F, Millet L, Grosset A, Herbert JM.

Eur J Pharmacol. 2006 Jan 4;529(1-3):172-8. Epub 2005 Dec 1.

PMID:
16325798
16.

Morphological and biochemical alterations of skeletal muscles from the genetically obese (ob/ob) mouse.

Kemp JG, Blazev R, Stephenson DG, Stephenson GM.

Int J Obes (Lond). 2009 Aug;33(8):831-41. doi: 10.1038/ijo.2009.100. Epub 2009 Jun 16.

PMID:
19528970
17.

Muscle protein turnover in the perfused hindquarters of lean and genetically obese-diabetic (db/db) mice.

Shargill NS, Ohshima K, Bray GA, Chan TM.

Diabetes. 1984 Dec;33(12):1160-4.

PMID:
6500191
18.

Mechanism of amelioration of insulin resistance by beta3-adrenoceptor agonist AJ-9677 in the KK-Ay/Ta diabetic obese mouse model.

Kato H, Ohue M, Kato K, Nomura A, Toyosawa K, Furutani Y, Kimura S, Kadowaki T.

Diabetes. 2001 Jan;50(1):113-22.

19.

Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonist.

Oana F, Takeda H, Matsuzawa A, Akahane S, Isaji M, Akahane M.

Eur J Pharmacol. 2005 Jul 25;518(1):71-6.

PMID:
15979609
20.

Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress.

Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S.

Metabolism. 2004 Apr;53(4):488-94.

PMID:
15045697
Items per page

Supplemental Content

Write to the Help Desk